Zydus receives final approval from the USFDA for Zolmitriptan Tablets USP
Capital MarketZydus Cadila has received the final approval from the USFDA to market Zolmitriptan Tablets, 2.5 mg and 5 mg. It is used to treat migraines. It helps to relieve headache, pain and other migraine symptoms (including nausea, vomiting and sensitivity to light/sound). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.
Powered by Capital Market - Live News